These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 21150236

  • 1. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
    Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS.
    Hematol Oncol Stem Cell Ther; 2010; 3(4):174-8. PubMed ID: 21150236
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P, Meloni A, Pistoia L, Gamberini MR, Cuccia L, Allò M, Putti MC, Spasiano A, Rosso R, Cecinati V, Righi R, Renne S, Peritore G, Vallone A, Positano V, Quaia E, Cademartiri F, Pepe A.
    Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
    [Abstract] [Full Text] [Related]

  • 3. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M, Cianciulli P, Caruso V, Romeo MA, Filosa A, Pitrolo L, Putti MC, Peluso A, Campisi S, Missere M, Midiri M, Gulino L, Positano V, Lombardi M, Ricchi P.
    J Cardiovasc Magn Reson; 2013 Jan 16; 15(1):1. PubMed ID: 23324167
    [Abstract] [Full Text] [Related]

  • 4. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2008 Feb 25; 10(1):12. PubMed ID: 18298856
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S, Zhang W, Huang L, Jiang H.
    PLoS One; 2013 Feb 25; 8(12):e82662. PubMed ID: 24376563
    [Abstract] [Full Text] [Related]

  • 6. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 25; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 7. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
    Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F.
    J Cardiovasc Magn Reson; 2013 May 20; 15(1):38. PubMed ID: 23688265
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 20; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 9. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A.
    Haematologica; 2011 Jan 20; 96(1):41-7. PubMed ID: 20884710
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar 20; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 11. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, Pattoneri P, Milazzo A, Cappellini MD.
    Ann Hematol; 2012 Sep 20; 91(9):1443-9. PubMed ID: 22572843
    [Abstract] [Full Text] [Related]

  • 12. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
    Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C.
    Eur J Haematol; 2010 Oct 20; 85(4):335-44. PubMed ID: 20561034
    [Abstract] [Full Text] [Related]

  • 13. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Oct 20; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
    Wahidiyat PA, Yosia M, Sari TT.
    Acta Med Indones; 2018 Apr 20; 50(2):168-176. PubMed ID: 29950538
    [Abstract] [Full Text] [Related]

  • 15. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL, Webthal® project.
    Blood Cells Mol Dis; 2024 Jul 20; 107():102859. PubMed ID: 38820707
    [Abstract] [Full Text] [Related]

  • 16. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2012 Jan 25; 14(1):8. PubMed ID: 22277065
    [Abstract] [Full Text] [Related]

  • 17. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May 25; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 18. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 19. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 15; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 20. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
    Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R.
    Blood; 2006 May 01; 107(9):3738-44. PubMed ID: 16352815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.